<DOC>
	<DOCNO>NCT01645449</DOCNO>
	<brief_summary>The purpose study compare evaluate single-dose oral bioavailability monitor safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Atorvastatin Calcium Tablets , 80 mg Dr. Reddy 's Under Fasting Conditions</brief_title>
	<detailed_description>An open label , balance , randomize , two-treatment , two-period , two-way crossover oral bioequivalence ' study Atorvastatin Calcium 80 mg Tablets Dr. Reddy 's Lipitor 80 mg Tablets Pfizer Ireland Pharmaceuticals healthy adult , human subject fast condition .</detailed_description>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Male female subject age 18 55 ( include ) year old . 2 . Subjects ' weight within normal range accord normal value Body Mass Index ( 1 8.0 30.0 kg/m2 ) minimum 50 kg weight . 3 . Subjects normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable range . 4 . Subjects normal 12lead electrocardiogram ( ECG ) . 5. systolic blood pressure 90 mmHg 145 mmHg ( age 18 45 year ) 90 mmHg 160 mmHg ( 45 year ) . Diastolic blood pressure 50 mrnHg 90 rnmHg . Pulse rate 45 bpm 100 bpm . 6 . Subjects negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , morphine ) . 7 . Subjects negative alcohol breath test . 8 . Women childbearing potential must use acceptable method birth control 4 week prior , 4 week last dose trial medication inform potential risk associate become pregnant enrol within clinical research trial . Accepted form contraception : i.e . implant , injectables , hormonal intrauterine device , combine oral contraceptive , sexual abstinence vasectomise sexual partner throughout trial . Female volunteer postmenopausal , hysterectomised surgically sterile may enrol . 9 . Subjects willing adhere protocol requirement provide write informed consent . The subject exclude study , meet follow criterion : 1 . Hypersensitivity test , reference drug , use ingredient , related class drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . Individual farniliy case medical history myopathy . 4 . Any treatment could bring induction inhibition hepatic microsomal enzyme system within 1 month first dose Period 1 . 5 . Medical history muscular toxic reaction treatment statins fibrates . 6 . Use prescribed OTC medication herbal supplement within 14 day within 5 time halflife respective active substance ( whatever longer ) , first dose Period 1 ( exclude contraceptive woman ) . 7 . History presence significant alcoholism drug abuse past one year . Alcoholism define consumption 50g ethanol per day ( 12.5 cL glass 10째 [ l0 % ] ] wine = 12 g ; 4 cL aperitif , 42째 [ 42 % ] whiskey = 17 g ; 25 cL glass 3째 [ 3 % ] beer = 7.5 g ; 25 cL glass 6째 [ 6 % ] beer = 15 g. 8 . History presence significant smoking ( 10 cigarettes/day ) . 9 . History presence asthma , urticaria significant allergic reaction . 10 . History presence significant gastric andlor duodenal ulceration . 11 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumor . 12 . History presence cancer . 13 . Difficulty donate blood . 14 . Difficulty swallow solid like tablet capsule . 15 . Major illness 3 month first dose Period 1 . 16 . Participation drug research study within past 1 month first dose Period 1 . 17 . Donation blood past 2 month first dose Period 1 . 18 . Consumption grapefruit juice , xanthinecontaining product alcohol within 48 hour prior dose . 19 . Positive screen test one : HIV , Hepatitis B Hepatitis C. 20 . History presence significant easy bruise bleeding . 21 . History presence significant recent trauma . 22 . Pregnancy breastfeeding ( female subject ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Atorvastatin calcium</keyword>
	<keyword>crossover</keyword>
</DOC>